| BioWorld

Alkermes Buying Reliant In Stock Purchase Worth $934M

Scooping up the shares it doesn’t already own, Alkermes Inc. agreed to purchase the remaining 81 percent of Reliant Pharmaceuticals LLC in a stock deal worth about $934 million. (BioWorld Today) Read More

PDL’s Stock Up 22 Percent On Poor Phase II Results

Test Ships Amyloid-Beta Plaques From Brain To Blood, Forecasts Alzheimer’s Onset Years Ahead

Ligand, Elan Get FDA Nod For Pain Treatment Avinza

Other News To Note

Cell Genesys Drops Gene Therapy Collaboration With GPC Biotech

Hemosol’s Stock Falls 29 Percent After Hemolink Denial In Canada

BioWorld

March 22, 2002

Alkermes Buying Reliant In Stock Purchase Worth $934M

PDL’s Stock Up 22 Percent On Poor Phase II Results

Test Ships Amyloid-Beta Plaques From Brain To Blood, Forecasts Alzheimer’s Onset Years Ahead

Ligand, Elan Get FDA Nod For Pain Treatment Avinza

Other News To Note

Cell Genesys Drops Gene Therapy Collaboration With GPC Biotech

Hemosol’s Stock Falls 29 Percent After Hemolink Denial In Canada

Today's news in brief

Today's news in brief

News in brief

In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty